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Abstract
Despite the high incidence and mortality of prostate cancer, the etiology of this disease is not fully
understood. In this study, we develop functional evidence for CBP and PTEN interaction in prostate cancer
based on ﬁndings of their correlate expression in the human disease. Cbppc/;Ptenpcþ/ mice exhibited
higher cell proliferation in the prostate and an early onset of high-grade prostatic intraepithelial neoplasia.
Levels of EZH2 methyltransferase were increased along with its Thr350 phosphorylation in both mouse
Cbp/; Ptenþ/ and human prostate cancer cells. CBP loss and PTEN deﬁciency cooperated to trigger a
switch from K27-acetylated histone H3 to K27-trimethylated bulk histones in a manner associated with
decreased expression of the growth inhibitory EZH2 target genes DAB2IP, p27KIP1, and p21CIP1. Conversely,
treatment with the histone deacetylase inhibitor panobinostat reversed this switch, in a manner associated
with tumor suppression in Cbppc/;Ptenpcþ/ mice. Our ﬁndings show how CBP and PTEN interact to
mediate tumor suppression in the prostate, establishing a central role for histone modiﬁcation in the etiology
of prostate cancer and providing a rationale for clinical evaluation of epigenetic-targeted therapy in patients
with prostate cancer. Cancer Res; 74(7); 2050–61. 2014 AACR.
Introduction
Prostate cancer is the most commonly diagnosed malig-
nancy and the second leading cause of cancer death in Amer-
ican men. Clinical prostate cancer is extremely rare in men
younger than 45 years of age, with less than 1 in 10,000
occurrences. The incidence increases dramatically over the
ensuing decades, with a 1 in 6 chance of cancer detection
between the ages of 60–80. Intriguingly, autopsy studies dem-
onstrate that high-grade prostatic intraepithelial neoplasia
(PIN) and small/microscopic carcinomas are present in
the prostate of up to 29% of men at 30 to 40 years of age (1).
These ﬁndings indicate that PIN/low-grade cancers fre-
quently develop in the prostate of adult men at an early
age. It is of paramount importance to elucidate the genetic/
epigenetic lesions responsible for early-stage pathogenesis
in the prostate.
The tumor suppressor gene PTEN is frequently mutated,
deleted, or expressed at reduced levels in human prostate
cancer (2, 3). Loss of heterozygosity (LOH) in the PTEN locus
occurs in up to 20% of localized but more than 60% of
advanced/metastatic prostate cancer, suggesting that PTEN
haploinsufﬁciency plays an important role in prostate cancer
initiation and development into the advanced/aggressive
stage. Mouse genetic studies show that Pten heterozygous
deletion alone fails to induce high-grade PIN until mice are
older than 12 months (4, 5), suggesting that monoallelic loss of
PTEN is insufﬁcient to initiate prostate neoplasia and that
cooperating oncogenic alterations are required.
CBP (CREB-binding protein, CREBBP) is a histone acet-
yltransferase that participates in many biologic processes,
including cell growth, transformation, and organ develop-
ment (6). Genome-wide analyses of histone modiﬁcation
show that histone acetylation generally correlates with gene
activation (7), which is consistent with the ﬁnding that both
mammalian and Drosophila CBP are involved in gene trans-
activation by mediating histone H3 lysine 27 acetylation
(H3K27Ac; refs. 8, 9). Gene inactivation mutations and
chromosomal translocations with breakpoints at the CBP
gene locus are frequently detected in different types of
hematologic malignancies, including acute lymphoblastic
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leukemia and B-cell lymphoma (10, 11). Mouse genetic
studies show that thymocyte-speciﬁc CBP deletion causes
T-cell lymphoma (12). These ﬁndings imply that CBP func-
tions as a hematologic tumor suppressor. Moreover, LOH at
the CBP locus has been reported in human solid tumors and
cancer cell lines, including PC-3 prostate cancer cells (13,
14). However, the relevance and the exact role of CBP in
prostate cancer pathogenesis are not fully understood. In the
present study, we demonstrate that reduced expression of
CBP correlates with PTEN expression in a cohort of human
prostate tumors. Concomitant deletion of Cbp and Pten
induces early-life high-grade PIN/low-grade cancer. Treat-
ment of Cbp/Pten compound-deﬁcient mice with the histone
deacetylase inhibitor panobinostat diminishes PIN lesions.
Materials and Methods
Generation of Cbp and Pten prostate-speciﬁc deletion
mice
Cbp conditional knockout (CbpL/L) mice were provided by
Dr. Jan van Deursen at Mayo Clinic (12). Pten conditional
knockout (PtenL/L) mice were originally generated in the
laboratory of Dr. Hong Wu at University of California Los
Angeles (Los Angeles, CA; ref. 15) and purchased from The
Jackson Laboratory. Pb-Cre4 transgenic mice generated in the
laboratory of Dr. Pradip Roy-Burman at University of Southern
California, Los Angeles, CA (16) were acquired from the
National Cancer Institute (NCI) Mouse Repository. Cohorts of
Cbppc/;Ptenpcþ/, CbpL/L;PtenL/þ, Cbppc/ and Ptenpcþ/
mice were generated from Cbppcþ/;Ptenpcþ/ males and
CbpL/þ;PtenL/þ females, whichwere obtained by cross breeding
Pb-Cre4 males with CbpL/L and PtenL/L females. All mice were
maintained under standard conditions of feeding, light, and
temperature with free access to food and water. All experi-
mental protocols were approved by the Institutional Animal
Care and Use Committee at Mayo Clinic.
PCR-based genotyping of mice
Genotyping of wild-type and conditional alleles of Cbp and
Pten genes as well as the Cre transgene was performed accord-
ing to previously described PCR protocols (12, 16, 17). Primer
sequences are provided in Supplementary Table S1.
Cell lines, cell culture, and transfection
DU145 cell line was purchased from the American Type
Culture Collection and cultured in RPMI-1640 (Invitrogen)
supplemented with 10% FBS (Hyclone). LAPC-4 cell line was
provided by Dr. Charles Sawyers (Memorial Sloan-Kettering
Cancer Center, New York, NY) and cultured in Iscove's
Modiﬁed Eagle Medium (IMEM) with 10% FBS. Pten-positive
and -negative MEFs were provided by Dr. Zhenbang Chen at
Meharry Medical College (Nashville, TN; ref. 18) and cultured
in Dulbecco's Modiﬁed Eagle Medium with 10% FBS. These
cell lines have been tested and authenticated (karyotyping,
AR expression, and PTEN mutation status) for less than 6
months before the ﬁrst submission of the manuscript. Cell
transfection was performed by electroporation using an
Electro Square Porator ECM 830 (BTX) as described pre-
viously (19).
Panobinostat (LBH589) treatment of mice
Six-month-old Cbppc/;Ptenpcþ/male mice were randomly
assigned into two groups (n ¼ 9/group) for treatment with
vehicle or LBH589 (20mg/kg/d)dailyby intraperitoneal injection
for 30 days. LBH589 was dissolved in 5% DMSO/PBS solution.
Human prostate cancer specimens, tissue microarray
construction, and immunohistochemistry
Three intermediate-density prostate cancer TMAs were
prepared by the Tissue and Cell Molecular Analysis Shared
Resource at the Mayo Clinic Cancer Center. These TMAs
contain cancerous (Gleason sum 4–9) and tumor-adjacent
benign tissues from the radical prostatectomy specimens of
78 patients with clinically localized prostate cancer (approx-
imately four cores per case). All cases upon collection into the
resource (approved by the Mayo Clinic Institutional Review
Board) had repeat pathology characterization of tissues and
review of medical records. IHC of TMA slides with antibodies
for CBP, PTEN, and p27KIP1 were performed as described in
Supplementary Information. Digital images of IHC-stained
TMA slides were obtained at 40 magniﬁcation (0.0625
mm2/raw image pixel) using a whole slide scanner (ScanScope
CS, Aperio).
Statistical Analysis
Cell culture experimentswere carried outwith three ormore
replicates. Statistical analyses were performed by the Student t
test for cell culture and mouse tissue studies. The Fisher exact
test (right tail) was used to measure the association of the
expression of CBP, PTEN, and p27KIP1 proteins in human
prostate cancer specimens. P values of <0.05 are considered
signiﬁcant.
Additional methods
Additional methods are provided in Supplementary
Information.
Results
Expression of CBP and PTEN protein correlates in
human prostate cancer specimens
mRNA-based analysis shows that CBP expression appears to
be lower in prostate cancers than in benign prostatic hyper-
plasias (20). An independent IHC study demonstrates that the
CBP protein is well expressed in both normal and malignant
human prostate tissues (21). Notably, CBP expression is
completely lost in a subset of primary tumors and lymph node
metastases, but not in any benign prostate tissues examined
(21). Because the previous ﬁndings regarding CBP expression
in human prostate cancers are not entirely consistent, we
employed TMA and IHC approaches to examine CBP protein
expression in a cohort of human prostate cancers (n ¼ 271
TMA specimens) and tumor-adjacent benign tissues (n ¼ 25
TMA elements) obtained from 78 patients. IHC staining was
evaluated on the basis of a semi-quantitative scale by consid-
ering both percentage of positive cells and staining intensity.
We found that approximately 80% of benign tissues, but only
about 45% of cancers expressed higher levels (staining index
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(SI)  6 of CBP protein; Supplementary Fig. S1A). Moreover,
approximately 20% of cancers, but not benign tissues
expressed none or low levels (SI < 3) of CBP protein. Repre-
sentative images of CBP staining in benign and cancerous
tissues are shown in Supplementary Fig. S1B. Statistical anal-
ysis of the quantitative data conﬁrmed that CBP expression
was signiﬁcantly lower in cancers than in benign tissues
(Supplementary Fig. S1C). IHC analysis in an additional cohort
of 20 non-TMA specimens demonstrated that CBP protein
level was signiﬁcantly lower in PIN lesions than that in the
adjacent benign tissues (Supplementary Fig. S2).
Because partial loss of PTEN is fairly common in human
prostate cancer (3, 22) and yet requires cooperating oncogenic
lesions in prostate oncogenesis (4, 23), we examined PTEN
expression in the cohort of TMA specimens and sought to
determine whether the expression of CBP and PTEN protein
correlates in these patients. Representative images of high and
low staining of CBP and PTENare shown in the top and bottom
panels of Fig. 1A, respectively. The Fisher exact test demon-
strated that reduced expression of CBP and PTEN protein
correlates in 271 TMA prostate cancer specimens (Fig. 1B).
Expression of these proteins also correlates with p27KIP1, a
common downstream target of them (see details below) in this
cohort of specimens (Fig. 1A, C, and D).
CBP and PTEN act synergistically in prostate cell
proliferation and tumor formation
To explore the role of CBP in prostate cancer pathogenesis,
we crossed Cbp conditional (CbpLoxp/Loxp, hereafter termed as
CbpL/L) mice (12) with probasin (Pb)-Cre transgenic mice (Pb-
Cre4) that express Cre recombinase in prostate epithelial cells
(16). Effective deletion of theCbp gene andproteinwas detected
by PCR and immunoﬂuorescent cytochemistry, respectively,
in Pb-Cre4;CbpL/þ (Cbppcþ/) and Pb-Cre4;CbpL/L (hereafter
termed as Cbppc/) mice (Supplementary Figs. S3A and S3B
and S4A). Similar to the Cre-negative control mice, no signs of
pathology were detected in all lobes of the prostate, including
anterior prostate (AP), dorsolateral prostate (DLP), and ventral
prostate (VP), inCbppc/micewithin 12months of age (Fig. 2A
and Supplementary Fig. S4B), indicating that cooperative onco-
genic lesions are required. Because the TMA data showed that
reduced expression of CBP and PTEN proteins correlates in
human prostate cancer specimens (Fig. 1B), we sought to
determinewhether concomitant deletion ofCbp and Pten genes
accelerates prostate cancer formation in mice. We established
cohorts of CbpL/L;PtenL/þ (Cre-negative control), Cbppc/,
Ptenpcþ/ and Cbppc/;Ptenpcþ/ males by intercrossing Pb-
Cre4, CbpL/L and PtenL/L (15) mice. PCR-based analysis demon-
strated that theCbp genewas almost completely deleted, but the
Pten gene was only partially deleted in all the lobes of the
prostates in Cbppc/;Ptenpcþ/ mice (Supplementary Fig.
S3C). As early as 4 months of age, more than 80% of
Cbppc/;Ptenpcþ/ mice (n ¼ 11) exhibited clear histologic
evidence of low-grade PIN (mouse PIN I and II) in all lobes,
including AP, DLP, and VP (Supplementary Table S2). At 6
months of age, focal high-grade PIN (mouse PIN III and IV) in
AP and DLP and low-grade PIN (mouse PIN II) in VP were
detected in 100% penetrance in Cbppc/;Ptenpcþ/mice exam-
ined (n¼ 20; Fig. 2AandSupplementaryFig. S4B; Supplementary
Table S2). In contrast, no PINwas detected in the prostates of all
Cbppc/ littermates examined at this age (n ¼ 15; Fig. 2A and
Supplementary Table S2). Similar to the earlier reports that
approximately 10% of Pten heterozygous mice develop PIN at
an age younger than 9 months (4, 5), low-grade PIN was
observed in only 1 of 12 Ptenpcþ/males and no PIN was
detected in the other 11 Ptenpcþ/ mice at 6 months of age
Figure 1. Correlation of CBP, PTEN,
and p27KIP1 protein expression in
human prostate cancer. A,
representative images of prostate
tumors exhibiting high and low
expression of CBP, PTEN, and
p27KIP1 proteins, respectively.
Scale bar, 50 mm. Insets show high
magniﬁcation images; scale bar,
10 mm. B–D, proportions of human
prostate cancers (n ¼ 271 TMA
elements) that show high (SI score
> 4) or low (SI score 4) expression
of CBP, PTEN, and p27KIP1
proteins. The correlation between
PTEN andCBP, PTEN and p27KIP1,
and CBP and p27KIP1 expression
was observed, as determined by
the Fisher exact test (right tail). The
number in parentheses is the
percentage of the number of cases
in each category over the number
of total cases examined.
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(Fig. 2A and Supplementary Table S2). No neoplastic changes
were detected in any CbpL/L;PtenL/þ control mice (n ¼ 16)
(Fig. 2A and Supplementary Table S2). These histologic data
indicate that loss of CBP cooperates with PTEN haploinsufﬁ-
ciency in prostate tumorigenesis. Accordingly, Ki-67 staining
signiﬁcantly increased in Cbppc/;Ptenpcþ/ prostates com-
pared with CbpL/L;PtenL/þ, Cbppc/, or Ptenpcþ/ counter-
parts (Fig. 2B and C), suggesting that combined inactivation
ofCBP and PTENpromotes prostate epithelial cell proliferation
in vivo.
Coregulation of p27KIP1 and DAB2IP expression by CBP
and PTEN in vitro and in vivo
To explore the molecular mechanism underlying CBP/
PTEN deletion-induced prostate cancer cell proliferation, we
used small interfering RNAs (siRNA) to knock down endog-
enous CBP and PTEN individually or in combination in
PTEN-positive human prostate cancer cell lines and mea-
sured the impact on cell-cycle control. Concomitant knock-
down of CBP and PTEN increased proliferation of DU145
cells (Fig. 3A and B), although the effect was not as robust as
in Cbp/Pten knockout mice (Fig. 2B and C). Knockdown of
CBP and PTEN either alone or in combination had little or
no effect on expression of several key cell-cycle–driven
proteins, including CDK1, CDK2, CDK6, and cyclin B1, with
an exception of cyclin D1 (Fig. 3B). In contrast, CBP and/or
PTEN knockdown markedly decreased the expression of the
CDK inhibitors p27KIP1 and p21CIP1 and the growth-inhib-
itory protein DAB2IP, expression of which is often down-
regulated in human prostate cancer (Fig. 3B; refs. 24, 25).
CBP and/or PTEN knockdown also downregulated expres-
sion of p27KIP1, p21CIP1, and DAB2IP mRNAs in DU145 cells
(Fig. 3C). Similar results were obtained in LAPC-4 cells
(Supplementary Fig. S5A and B).
Next, we examined the impact of Cbp and Pten deletion on
expression of p27Kip1, p21Cip1, and Dab2ip proteins in the
mouse prostate. Nuclear expression of Cbp protein, nuclear,
and cytoplasmic expression of Pten protein and no expression
of phosphorylated Akt (Akt-p) was observed in prostate epi-
thelial cells of CbpL/L;PtenL/þ control mice (Fig. 4A–D, left). As
expected, Pten expression was reduced in the noncancerous
prostate epithelium in Cbppc/;Ptenpcþ/mice (Fig. 4C, mid-
dle), but surprisingly Pten protein was hardly detected in PIN
lesions in the samemice (Fig. 4C, right). Accordingly, Akt-pwas
robustly elevated in PIN, but not in the adjacent normal
epithelium in Cbppc/;Ptenpcþ/ mice (Fig. 4D, middle and
right). P27Kip1 and Dab2ip proteins were well expressed in
both cytoplasm and nucleus in the normal prostate epithelium
of control mice (Fig. 4E and F, left). Consistent with decreased
expression of Cbp and Pten and increased expression of Akt-
p, there were less cells expressing p27Kip1 and Dab2ip proteins
in PIN lesions in Cbppc/;Ptenpcþ/ mice than in the normal
prostates of control littermates (Fig. 4E and F, right). The
speciﬁcity of the antibodies for p27Kip1 and Dab2ip proteins
Figure 2. Concomitant deletion of
two Cbp alleles and one Pten allele
induces high-grade PIN and
enhances prostatic epithelial cell
proliferation. A,H&Eof anterior (AP)
and dorsolateral (DLP) prostates of
6-month-old CbpL/L;PtenL/þ (wild-
type), Cbppc/, Ptenpcþ/, and
Cbppc/;Ptenpcþ/ mice. Scale
bar, 50 mm. B and C, Ki-67 staining
analysis in the prostates of
6-month-old CbpL/L;PtenL/þ,
Cbppc/, Ptenpcþ/, and
Cbppc/;Ptenpcþ/ mice.
Representative images of Ki-67
staining in each genotype are
shown in B and quantitative data
are shown in C. Scale bar, 50 mm.
, P < 0.01.
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were demonstrated by siRNA knockdown and IHC assays
(Supplementary Fig. S6A and S6B). The IHC staining for Cbp,
Pten, Akt-p, p27Kip1, and Dab2ip was quantiﬁed and the data
are shown in Supplementary Fig. S7. Despite multiple efforts,
we were unable to validate an antibody that can effectively
detect p21Cip1 protein in mouse prostate sections by IHC. We
conclude that knockdown or knockout of CBP and PTEN
inhibits expression of p27KIP1, p21CIP1, and DAB2IP in human
prostate cancer cells and p27Kip1 and Dab2ip expression in the
mouse prostate. Moreover, p27KIP1 is a known tumor suppres-
sor that is often downregulated in human prostate cancer (26).
IHC staining and correlation studies showed that reduced
expression of p27KIP1 correlates with CBP and PTEN expres-
sion in the cohort of 271 TMA specimens of human prostate
cancer (Fig. 1A, C, andD). These data suggest that expression of
p27KIP1 protein may also be regulated by CBP and/or PTEN in
human prostate cancer.
CBP and PTEN regulation of H3K27Ac and H3K27me3 in
human and mouse prostate cancer cells
CBP as a histone acetyltransferase responds for the "open"
chromatin mark histone H3 lysine 27 acetylation (H3K27Ac)
and gene activation in mammals and ﬂies (8, 27, 28). In
contrast, the histone methyltransferase EZH2 mediates the
"close" chromatin mark H3 lysine 27 trimethylation
(H3K27me3) and gene repression (29). It has been shown
recently that CDK-dependent phosphorylation of EZH2 at
threonine 350 (T350-p) is important for EZH2-mediated
H3K27me3 and gene repression (19, 30, 31). Consistent with
the report that PTEN inactivation increases CDK enzymatic
activity and promotes cell-cycle progression (32), we found
that Pten homozygous deletion in MEF or knockdown in
DU145 human prostate cancer cells increases the overall levels
of T350 (T345 inmouse) phosphorylated EZH2 and H3K27me3
levels (Fig. 5A and B). PTEN inactivation also increased total
Figure 3. Effect of CBP and PTEN
knockdown on human prostate
cancer cell proliferation and
expression of cell cycle-regulatory
genes. A, DU145 prostate cancer
cells were transfected as indicated
and then seeded into 96-well plates
for MTS assays. Data are means 
SD from experiments with four
replicates (n ¼ 4). , P < 0.01,
comparing siPTENþsiCBP group
with siC group. B, DU145 cells
were transfected as in A for 48
hours followed by Western blot
analyses. The density of p27KIP1,
p21CIP1, and DAB2IP was
determinedbynormalizing toERK2
(loading control) ﬁrst and then to
the normalized value in siC-
transfected cells. C, DU145 cells
were transfected as in A for 36
hours followed by RT-qPCR
analysis. Data, means  SD. from
experiments with three replicates
(n¼ 3). , P < 0.01 and , P < 0.05.
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EZH2 levels in bothMEF andDU145 cells (Fig. 5A andB), which
is consistent with early reports that EZH2 protein and mRNA
are upregulated in prostate cancers in Nkx3.1þ/;Ptenþ/
compound and Ptenpc/mice (33, 34). Accordingly, CBP and
PTEN knockdown alone or together resulted in concomitant
upregulation of H3K27me3 and downregulation of H3K27Ac,
an H3K27Ac-to-H3K27me3 switch in bulk histones in both
DU145 and LAPC-4 cell lines (Fig. 5C–E and Supplementary
Fig. S5A). Moreover, we recently identiﬁedDab2ip, p27Kip1, and
p21Cip1 as Ezh2 targets inmouse embryonic stem cells (35) and
this ﬁnding was conﬁrmed by ChIP-qPCR in DU145 cells
(Supplementary Fig. S8). Consistent with the changes in the
overall levels of H3K27Ac and H3K27me3 (Fig. 5C–E), codeple-
tion of PTEN and CBP resulted in concomitant increase in
H3K27me3 (except the p21CIP1 locus) anddecrease inH3K27Ac
at these gene loci in DU145 cells (Supplementary Fig. S9).
H3K27Ac levels were lower but H3K27me3 levels weremuch
higher in PIN lesions in Cbp/Pten double knockout mice (Fig.
6A and B, right) compared with adjacent normal prostate
epithelial cells in Cbp/Pten-deﬁcient mice and normal prostate
epithelium in control mice (Fig. 6A and B, middle and left).
Accordingly, the levels of total and T345-phosphorylated Ezh2
were higher in Cbp/Pten double knockout PIN relative to
adjacent normal prostate epithelium in both Cbp/Pten deﬁ-
cient andwild-type controlmice (Fig. 6C andD). Although total
Ezh2 levels markedly increased (Fig. 6C), the level of serine 21
phosphorylation (S21-p), which inhibits EZH2's H3K27me3
activity (36), was only modestly elevated in PIN compared
with the adjacent noncancerous Cbp/Pten-deﬁcient cells (Fig.
6E). The speciﬁcity of antibodies for EZH2, T350-p, S21-p, and
H3K27me3 was demonstrated by siRNA knockdown and IHC
assays (Supplementary Fig. S6C) or described previously
Figure 4. Immunohistochemical
analysis of protein expression in
prostate sections of Cbp/Pten-
deﬁcient and "wild-type" mice.
A, H&E of prostate sections of 6-
month-old CbpL/L;PtenL/þ and
Cbppc/;Ptenpcþ/ mice. Scale
bar, 50 mm. Insets show high
magniﬁcation images; scale bar,
10 mm. N, normal; PIN, prostatic
intraepithelial neoplasia. B–F,
immunohistochemical analysis of
prostate sections of 6-month-old
CbpL/L;PtenL/þ and Cbppc/;
Ptenpcþ/ mice for expression of
Cbp (B), Pten (C), Akt-p (serine 473
phosphorylation; D), p27Kip1 (E),
and Dab2ip (F).
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(19, 36, 37). The quantiﬁed IHC data of H3K27Ac, H3K27me3,
Ezh2, T345-p, and S21-p are shown in Supplementary Fig. S10.
These data indicate that depletion of CBP and PTEN cooper-
atively induces a decrease in H3K27Ac and an increase in
H3K27me3 in bulk histones in human prostate cancer cells and
an H3K27Ac-to-H3K27me3 switch in the mouse prostate.
The histone deacetylase inhibitor panobinostat reverses
neoplastic growth in Cbp/Pten deletion prostates inmice
Because of the competitive nature of H3K27Ac and
H3K27me3 modiﬁcations on the same lysine residue and the
H3K27Ac-to-H3K27me3 switch induced by CBP and PTEN
knockdown or knockout, we sought to determine whether the
treatment of Cbp/Pten-deﬁcient tumors with the histone dea-
cetylase (HDAC) inhibitor would reverse the H3K27Ac-to-
H3K27me3 ratio and induce tumor repression. Cinnamic acid
hydroxamate panobinostat (LBH589) inhibits classes I and II
HDACs (38) and is currently being tested in clinical trials
for various malignancies, including prostate cancer (39, 40).
We, therefore, measured the therapeutic effect of LBH589 on
prostate tumor growth in Cbppc/;Ptenpcþ/ mice. 6-month-
old Cbppc/;Ptenpcþ/ mice were randomly assigned for
treatment with vehicle or LBH589 (20 mg/kg body weight;
n¼ 9/group).We found that LBH589 not only inhibited disease
progression, but also induced tumor regression by decreasing
the incidence of PIN lesions in Cbp/Pten knockout mice (Fig.
7A). Moreover, LBH589 treatment induced nuclear condensa-
tion, Akt phosphorylation (Akt-p) inhibition, increase in
H3K27Ac, and decrease in H3K27me3 levels in the prostates
of Cbppc/;Ptenpcþ/ mice (Fig. 7B). It has been shown
recently that treatment of chondrocytes with SAHA, another
HDAC inhibitor, increased expression of PHLPP1, a known
AKT phosphatase (41). Similarly, we found that LBH589
treatment of DU145 cells resulted in a moderate increase in
PHLPP1 expression (Supplementary Fig. S11A). These data
suggest that panobinostat-induced inhibition of AKT phos-
phorylation can be attributed, at least in part, to PHLPP1
upregulation although our data cannot rule out other mechan-
isms of panobinostat action on AKT.
Further ChIP analysis showed that LBH589 treatment
induced an increase in H3K27Ac and a decrease in
H3K27me3 levels at DAB2IP and p21CIP1 gene loci in CBP
and PTEN coknockdown DU145 cells (Fig. 7C and Supple-
mentary Fig. S11B). LBH589 also increased H3K27Ac but
decreased H3K27me3 levels on bulk histones in CBP/PTEN
double knockdown DU145 cells (Fig. 7D). Ki-67 staining and
terminal deoxynucleotidyl transferase–mediated dUTP nick
end labeling (TUNEL) assays demonstrated that treatment
with LBH589 decreased cell proliferation and increased
apoptosis in the prostates of Cbppc/;Ptenpcþ/ mice (Fig.
7E). The IHC staining for Akt-p, H3K27Ac, H3K27me3, Ki-67,
and TUNEL staining was quantiﬁed and the data are shown
in Supplementary Fig. S11C–S11G. The effect of LBH589 on
apoptosis was further conﬁrmed by its induction of changes
Figure 5. Effect of CBP and PTEN
deﬁciency on expression of total
and T350-phosphorylated EZH2,
H3K27Ac andH3K27me3 levels on
bulk histones. A, Western blot
analysis of indicated proteins in
Pten-proﬁcient (þ/þ) and -deﬁcient
(/) MEFs. B, DU145 cells
transfected as indicated for 48
hours followed by Western blot
analysis. C–E, DU145 cells were
transfected as indicated for 36
hours. Cytosolic (PTEN, ERK2) and
nuclear (CBP, H3K27Ac,
H3K27me3 and H3) extracts were
prepared for Western blot
(chemiluminescence-based)
analysis of expression of indicated
proteins (C). The relative
expression of H3K27Ac and
H3K27me3 was determined by
normalizing to histone H3 ﬁrst and
then to the normalized value in
siC-transfected cells and the
quantitative data are shown in
D and E, respectively. The
experiments were repeated twice.
Similar results were obtained from
these experiments and the data
shown was from one experiment.
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in expression of genes involved in apoptotic signaling path-
ways, including downregulation of the antiapoptotic pro-
teins XIAP and BCL-xL and cleavage of caspase-3 and PARP
(Supplementary Fig. S12A–S12C). Thus, the HDAC inhibitor
LBH589 induces regression of PIN lesions in Cbppc/;
Ptenpcþ/ mice via both inhibition of cell proliferation and
induction of apoptosis.
Discussion
CBP is implicated in human cancers (10, 11), but its precise
role in prostate oncogenesis remains elusive. For the ﬁrst time,
we provide in vivo evidence thatCbpdeletion induces high-grade
PIN/low-grade cancer in the mouse prostate in a Pten hetero-
zygous background. We further demonstrate that reduced
expression of CBPcorrelates with decreased expression of PTEN
in a cohort of human prostate cancer specimens. Thus, we have
established a clinically relevant mouse model that recapitulates
the pathogenesis of early-stage prostate cancer.
Genome-wide analyses show that histone acetylation gen-
erally correlates with gene activation (7). CBP mediates
H3K27Ac inmammals and ﬂies (8, 9), whereas EZH2 promotes
H3K27me3 (29). In line with the fact that H3K27Ac and
H3K27me3 modiﬁcations occur on the same lysine, CBP
antagonizes PcG protein-mediated gene silencing in Drosoph-
ila (8). We demonstrated for the ﬁrst time in mammalian cells
that codepletion of CBP and PTEN induces an H3K37Ac-to-
H3K27me3 switch in bulk histones. This observation is sub-
stantiated by our ﬁnding that PTEN inactivation results in
EZH2 activation by increasing expression of total and T350-
phosphorylated EZH2 in MEF, human prostate cancer cell
lines, and in the mouse prostate. These ﬁndings support a
model (Fig. 7F) wherein deletion of CBP alone reduces
H3K27Ac levels at EZH2 target gene loci and compromises
their expression. Upregulation of EZH2 protein and function
(via T350 phosphorylation) due to PTEN inactivation increases
the level of the H3K27me3 histonemark, which further reduces
or completely shuts off the expression of EZH2 target genes,
thereby favoring tumor formation. This model is further val-
idated by the observation that expression of EZH2 target genes
is downregulated owe to CBP and/or PTEN codepletion. The
coordinative effect of CBP loss and EZH2 activation on gene
repression triggered by PTEN loss provides a plausible expla-
nation as to why CBP deletion alone is insufﬁcient to induce
neoplastic changes in the prostate. Given that inactivation
mutations of CBP gene are frequently detected in human
Figure 6. Immunohistochemical
analysis of H3K27Ac, H3K27me3
and total, T345- and S21-
phosphorylated Ezh2 in prostate
sections of Cbp/Pten-deﬁcient
mice (Cbppc/;Ptenpcþ/) and
"wild-type" littermate controls
(CbpL/L;PtenL/þ). Prostate sections
of 6-month-old mice were used for
immunohistochemical analysis of
expression of H3K27Ac (A),
H3K27me3 (B), total Ezh2 (C),
T345-phosphorylated Ezh2 (D), and
S21-phosphorylated Ezh2 (E).
Scale bar, 50 mm. Insets show high
magniﬁcation images; scale bar, 10
mm. N, normal; PIN, prostatic
intraepithelial neoplasia.
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Figure 7. Histone deacetylase inhibitor panobinostat (LBH589) induces tumor repression, cell proliferation inhibition, and apoptosis in Cbppc/;Ptenpcþ/
mice. A, 6-month-old Cbppc/;Ptenpcþ/ mice (n ¼ 9 per group) were sacriﬁced (column 1) or treated with vehicle or LBH589 (20 mg/kg/d) for 1 month
and then sacriﬁced (columns 2 and 3). Prostate tissues were harvested, sectioned, and H&E stained. Sections with comparable acini numbers in each
group were examined for PIN acini. The data were obtained in a blinded fashion. M, month. , P < 0.05. B, histologic and immunohistochemical
analysis of Akt-p, H3K27Ac, and H3K27me3 in prostate sections of mice treated with vehicle or LBH589. Scale bar, 50 mm. Insets show high
magniﬁcation images; scale bar, 10 mm. C, effect of LBH589 on H3K27Ac and H3K27me3 levels at the DAB2IP gene locus in PTEN/CBP knockdown
DU145 cells. Cells were transfected with CBP and PTEN-speciﬁc siRNAs for 24 hours and treated with 20 nmol/L LBH589 for 24 hours followed by
ChIP analysis with H3K27Ac andH3K27me3 antibodies. Enrichment of H3K27Ac andH3K27me3was determined byChIP-qPCR (n¼ 3). ,P < 0.01. D, effect
of LBH589 on expression of H3K27Ac and H3K27me3 of bulk histones in PTEN/CBP knockdown DU145 cells. Cells were transfected as in C for 24 hours,
treated with LBH589 at different doses (5, 10, 20 nmol/L) for 24 hours followed by Western blot analysis. The density of H3K27Ac and H3K27me3 was
determined by normalizing to H3 ﬁrst and then to the normalized value in mock-treated cells. E, Ki-67 staining and TUNEL assay were performed on
prostate sections obtained from mice used in experiments as described in A. Scale bar, 50 mm. Insets show high magniﬁcation images; scale bar, 10 mm. F,
diagram deciphering the synergistic effect of CBP and PTEN codeﬁciency on the H3K27Ac-to-H3K27me3 switch on chromatin and their impact on gene
expression. Light purple circles represent nucleosomes.
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recurrent lymphomas and small-cell lung cancers (10, 11, 42), it
is possible that like in the prostate, CBP, a generic histone
acetyltransferase (6) may act as a tumor suppressor in a
context-dependent manner in those types of tissues.
Besides its overexpression in metastatic prostate cancer,
EZH2 was found signiﬁcantly upregulated in benign prostatic
hyperplasia and primary prostate cancer (43). EZH2 overex-
pression in early lesions such as PIN is also observed in Pten-
knockout mice (34). Thus, in addition to its role in late-stage
castration-resistant prostate cancer (37), there is ample evi-
dence suggesting that deregulated EZH2 also plays a pivotal
role in the early-stage pathogenesis of prostate cancer. This
notion is fully supported by ourmodel wherein EZH2 is crucial
for Cbp/Pten deletion-induced tumorigenesis in the prostate
(Fig. 7F).
AKT is invariably activated in PTEN-null prostate cancer
(15). Transgenic expression of constitutively active AKT alone
induces PIN in the mouse prostate (44), suggesting that AKT
activation itself is sufﬁcient to drive prostate epithelial cell
transformation and early-stage prostate cancer pathogenesis.
The ﬁnding in mouse models is substantiated by the obser-
vation that AKT phosphorylation is signiﬁcantly elevated at
human PIN (45). Intriguingly, we found that Akt is highly
phosphorylated in PIN, but not in the adjacent nonmalignant
prostatic epithelial cells in Cbppc/;Ptenpcþ/mice and in the
prostatic epithelium in "wild-type" mice. Thus, homozygous
Cbp deletion in Pten heterozygous background predisposes the
prostatic epithelium for secondary genetic and/or epigenetic
lesions, which may in turn lead to Akt activation and prostate
tumorigenesis. Further analysis is warranted to deﬁne the
molecular basis underlying Akt activation in PIN lesions in
Cbp/Pten compound-deﬁcient mice.
An early study demonstrates that AKTphosphorylates EZH2
at S21 and inhibits EZH2's H3K27me3 activity (36). An inde-
pendent study reports that T350 but not S21 phosphorylation
was readily detected by mass spectrometry in 293T cells (30),
suggesting that the overall level of S21 phosphorylationmay be
lower than T350 phosphorylation in these cells. Moreover, it
has been shown recently that although both androgen-sensi-
tive LNCaP and castration-resistant abl prostate cancer cells
are PTEN-negative, surprisingly, EZH2 S21 phosphorylation
was barely detected in LNCaP but was much higher in abl (37),
implying that in addition to PTEN loss, other defects are
essential for AKT-mediated S21 phosphorylation in prostate
cancer cells. Indeed, besides PTEN loss, AKT is hyperactivated
due to decreased expression of the AKT phosphatase PHLPP1
and the impaired FKBP51-PHLPP1 complex in abl cells under
androgen depletion conditions (34, 37). In agreement with the
ﬁndings from these studies, we found that although Akt was
activated in PIN in non-castrated Cbp/Pten knockout mice
(Fig. 4D), only very modest S21 phosphorylation of Ezh2 was
detected in these tissues (Fig. 6E). In contrast, both total
Ezh2 and T350 phosphorylation, an indicator of Ezh2 acti-
vation (19, 30, 31), was substantially upregulated (Fig. 6C and
D), which is consistent with high levels of H3K27me3 in
these tissues (Fig. 6B and Supplementary Fig. S10). Based
upon the ﬁndings from our mouse model and others from
human prostate cancers and cell lines (37), it can be pos-
tulated that S21 phosphorylation-mediated inhibitory effect
on EZH2's H3K27me3 activity is minimal in uncastrated
PTEN-deﬁcient prostate tumors like those in Cbp/Pten dele-
tion mice. In castration-resistant prostate cancer, however,
the H3K27me3-dependent Polycomb function of EZH2 may
be mitigated due to aberrant activation of AKT and subse-
quent S21 hyperphosphorylation of EZH2 (37).
A pilot phase I clinical study showed that the anticancer
effect of oral panobinostat (LBH589) on castration-resistant
prostate cancer was not quite promising, even though
increased histone acetylationwas observed in peripheral blood
mononuclear cells (40), suggesting that new biomarkers are
needed to identify patients with prostate cancer who are
responsive to HDAC inhibitors. Inactivation mutations in the
CBP gene frequently recur in relapsed lymphoblastic leukemia
and B-cell lymphoma (10, 11) and that Cbp deletion induces T-
cell lymphoma in mice (12). Notably, patients with lymphoma
respond favorably to the HDAC inhibitor. In a striking simi-
larity, we demonstrated that both CBP and PTEN protein
expression is downregulated in a large cohort of human
prostate cancer samples and that LBH589 treatment induces
regression of Cbp/Pten-deﬁcient PIN in mice. Our ﬁndings
suggest that CBP- and PTEN-deﬁcient prostate cancer patients
may be susceptible to the HDAC inhibitory drugs (Fig. 7F).
In summary, we demonstrate that concomitant deletion of
twoCbp alleles and one Pten allele induces early-life high-grade
PIN/low-grade cancer in the mouse prostate. Of note, whether
PTEN is lost in human PIN lesions has recently been called into
question (46), suggesting a potential weakness in our model.
Nonetheless, we further show that codeﬁciency of CBP and
PTEN increases cell proliferation, induces an acetylation-to-
trimethylation shift on lysine 27 of pan histone H3, and causes
transcriptional repression of DAB2IP and p27KIP1 tumor sup-
pressor proteins of EZH2 targets. Our model not only recapi-
tulates the pathogenesis of early-stage prostate cancer, but also
is highly clinically relevant as expression of CBP, PTEN, and
p27KIP1 correlates in human prostate cancer. Our ﬁnding that
treatment of Cbppc/;Ptenpcþ/ mice with panobinostat
induces regression of PIN implies that deregulated CBP and
PTEN may serve as a biomarker for epigenetic-targeted ther-
apy of human prostate cancers.
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